A new paper in the Journal of Urology provides us with some interesting if preliminary information on the ways that genetic/genomic tests of biopsy samples may be affecting first-line treatments for localized forms of prostate cancer. We can comment at this time only on the abstract of the new paper by Shore et al. (since […]![]()
